Monaco Asset Management SAM Has $833,000 Stock Position in Arvinas, Inc. $ARVN

Monaco Asset Management SAM lowered its position in shares of Arvinas, Inc. (NASDAQ:ARVN) by 90.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 70,253 shares of the company’s stock after selling 640,683 shares during the quarter. Monaco Asset Management SAM’s holdings in Arvinas were worth $833,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. ProShare Advisors LLC lifted its holdings in shares of Arvinas by 7.2% during the fourth quarter. ProShare Advisors LLC now owns 14,827 shares of the company’s stock worth $176,000 after buying an additional 993 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of Arvinas by 3.6% during the third quarter. Intech Investment Management LLC now owns 32,653 shares of the company’s stock worth $278,000 after buying an additional 1,125 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Arvinas by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock worth $271,000 after buying an additional 2,122 shares in the last quarter. Oxford Asset Management LLP lifted its holdings in shares of Arvinas by 15.5% during the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock worth $123,000 after buying an additional 2,242 shares in the last quarter. Finally, Entropy Technologies LP lifted its holdings in shares of Arvinas by 8.6% during the third quarter. Entropy Technologies LP now owns 35,295 shares of the company’s stock worth $301,000 after buying an additional 2,804 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Insiders Place Their Bets

In other Arvinas news, Director Briggs Morrison bought 20,000 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were purchased at an average price of $13.40 per share, for a total transaction of $268,000.00. Following the completion of the transaction, the director directly owned 96,021 shares in the company, valued at approximately $1,286,681.40. The trade was a 26.31% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Randy Teel sold 9,657 shares of Arvinas stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $95,990.58. Following the completion of the transaction, the chief executive officer owned 287,218 shares in the company, valued at approximately $2,854,946.92. This represents a 3.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 42,467 shares of company stock worth $427,598. Insiders own 7.30% of the company’s stock.

Arvinas Stock Performance

Shares of NASDAQ ARVN opened at $8.98 on Monday. Arvinas, Inc. has a 52 week low of $6.05 and a 52 week high of $14.51. The stock has a market capitalization of $579.39 million, a P/E ratio of -2.70 and a beta of 1.75. The stock’s fifty day moving average is $10.20 and its 200 day moving average is $11.61.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.05. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The company had revenue of $15.60 million for the quarter, compared to analysts’ expectations of $16.61 million. During the same quarter last year, the business earned $1.14 earnings per share. Arvinas’s revenue was down 91.7% on a year-over-year basis. Equities research analysts forecast that Arvinas, Inc. will post -2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ARVN shares. Wedbush raised their price target on Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 24th. Wall Street Zen cut Arvinas from a “hold” rating to a “sell” rating in a research report on Monday, March 2nd. Citigroup raised their price target on Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Weiss Ratings cut Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 19th. Finally, Truist Financial set a $10.00 price target on Arvinas in a research report on Wednesday, March 18th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $14.69.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.